Last updated on September 2020

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: HIV-1-infection
  • Age: Between 12 - 100 Years
  • Gender: Male or Female

Key Inclusion Criteria:

  • Adult aged 18 years (at all sites) or adolescent aged 12 and weighing 35 kg (at sites in North America and Dominican Republic)
  • Currently receiving a stable failing antiretroviral (ARV) regimen for > 8 weeks
  • Have HIV-1 RNA 400 copies/mL at screening
  • Have multidrug resistance
  • Have no more than 2 fully active ARV remaining from the 4 main classes that can be effectively combined to form a viable regimen
  • Able and willing to receive an optimized background regimen together with lenacapavir
  • No Hepatitis C virus (HCV) ongoing infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.